385 related articles for article (PubMed ID: 21948465)
1. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
Jeyaretna DS; Kuroda T
Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809
[TBL] [Abstract][Full Text] [Related]
3. Modification of HSV-1 to an oncolytic virus.
Nakashima H; Chiocca EA
Methods Mol Biol; 2014; 1144():117-27. PubMed ID: 24671680
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
7. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
8. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
9. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
12. [Development of conditionally replicating oncolytic HSV vector--targeted gene therapy for sarcoma by oncolytic viruses].
Takahashi K; Yamamura H
Nihon Rinsho; 2006 Mar; 64 Suppl 3():326-33. PubMed ID: 16615493
[No Abstract] [Full Text] [Related]
13. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
14. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
Kuroda T; Martuza RL; Todo T; Rabkin SD
BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
16. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]